Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Scientific Officer

Chief Medical Officer

See Remarks

Chief Human Resources Officer

Chief Financial Officer

Chief Legal Officer

President & CEO

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in t...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-01	Premium	sold	Premium	Premium	Premium	-
2024-04-01	Premium	acquired	Premium	Premium	Premium	-
2024-03-04	Premium	acquired	Premium	Premium	Premium	-
2024-03-04	Premium	sold	Premium	Premium	Premium	-
2024-02-29	Premium	acquired	Premium	Premium	Premium	-
2024-02-29	Premium	sold	Premium	Premium	Premium	-
2024-02-20	Premium	gifted	Premium	Premium	Premium	-
2024-02-07	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2024-02-07	Premium	sold	Premium	Premium	Premium	-
2024-02-06	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-02-06	Premium	acquired	Premium	Premium	Premium	-
2024-01-02	Premium	sold	Premium	Premium	Premium	-
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2023-12-26	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-12-26	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-12-26	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-12-22	Premium	sold	Premium	Premium	Premium	Chief Human Resources Officer
2023-12-22	Premium	acquired	Premium	Premium	Premium	Chief Human Resources Officer
2023-12-20	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-12-20	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2023-12-20	Premium	sold	Premium	Premium	Premium	Chief Human Resources Officer
2023-12-20	Premium	sold	Premium	Premium	Premium	See Remarks
2023-12-20	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-12-20	Premium	sold	Premium	Premium	Premium	See Remarks
2023-12-19	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer

CERE - Cerevel Therapeutics Holdings, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for CERE